Company intelligence / Profile preview

KoVax

Tel Aviv, Israel

Ownership: Private
Development stage: Other

Overview

KoVax developed veterinary vaccines for aquaculture, with its KV3 vaccine commercially used for prevention of koi herpesvirus in carp. The company brought innovative products to market and maintained an active pipeline before its acquisition by Phibro Animal Health Corporation

Therapeutic areas: Infectious Diseases
Modalities: Vaccine
Industry: Veterinary

Partnerships

Phibro Animal Health Corporation (acquirer & strategic partner)

Beyond the preview

Go deeper on KoVax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KoVax.

Explore the full profile